{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:46Z","timestamp":1791216466153,"version":"4.1.0"},"reference-count":87,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most patients, the standard of treatment has long consisted on low-molecular-weight heparin followed by vitamin K antagonists, but a number of clinical trials and, subsequently, post-marketing studies have shown that direct oral anticoagulants (DOACs) with or without lead-in heparin therapy are effective alternatives with fewer adverse effects. This evidence has led to important changes in the guidelines on the treatment of VTE, including pulmonary embolism (PE), with the DOACs being now recommended as the first therapeutic choice. Additional research has contributed to identifying low-risk PE patients who can benefit from outpatient management or from early discharge from the emergency department with DOAC treatment. There is evidence to support the use of DOACs in intermediate-risk PE patients as well as in high-risk patients receiving thrombolytic treatment. The use of DOACs has also been proven to be safe and effective in special populations of PE patients, such as patients with renal impairment, liver impairment, and cancer.<\/jats:p>","DOI":"10.1055\/a-2105-8736","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:01:10Z","timestamp":1710201670000},"page":"206-217","source":"Crossref","is-referenced-by-count":7,"title":["Direct Oral Anticoagulants for Pulmonary Embolism"],"prefix":"10.1055","volume":"44","author":[{"given":"Roberto","family":"Pizzi","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Thrombosis Center, Ospedale di Circolo di Varese and Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica Anna","family":"Cimini","sequence":"additional","affiliation":[{"name":"Vascular and Internal Medicine- Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine and Thrombosis Center, Ospedale di Circolo di Varese and Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[{"name":"Vascular and Internal Medicine- Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","article-title":"The epidemiology of venous thromboembolism in the community","volume":"28","author":"J A Heit","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"I4","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"R H White","year":"2003","journal-title":"Circulation"},{"issue":"9828","key":"ref3","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"S Z Goldhaber","year":"2012","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"133","author":"C Kearon","year":"2008","journal-title":"Chest"},{"issue":"15","key":"ref5","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"363","author":"The EINSTEIN PE Investigators","year":"2010","journal-title":"N Engl J Med"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"S Schulman","year":"2014","journal-title":"Circulation"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2352-3026(16)30080-1","article-title":"Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study","volume":"3","author":"M PA Brekelmans","year":"2016","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"19","key":"ref12","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"ref15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0038-1676611","article-title":"Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry","volume":"119","author":"W Ageno","year":"2019","journal-title":"Thromb Haemost"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.04.036","article-title":"Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE","volume":"191","author":"H Bounameaux","year":"2020","journal-title":"Thromb Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.thromres.2020.09.001","article-title":"ETNA-VTE Europe: benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months","volume":"196","author":"G Agnelli","year":"2020","journal-title":"Thromb Res"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.amjmed.2020.03.036","article-title":"Profile of patients diagnosed with acute venous thromboembolism in routine clinical practice: the RE-COVERY DVT\/PETM study","volume":"133","author":"S Z Goldhaber","year":"2020","journal-title":"Am J Med"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"W Ageno","year":"2016","journal-title":"Lancet Haematol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/rth2.12489","article-title":"Anticoagulant treatment for venous thromboembolism: a pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies","volume":"5","author":"S Haas","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2019.02.010","article-title":"XALIA-LEA: an observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America","volume":"176","author":"R Kreutz","year":"2019","journal-title":"Thromb Res"},{"issue":"41","key":"ref23","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/eurheartj\/ehu243","article-title":"Management of venous thrombo-embolism: an update","volume":"35","author":"S Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/jamainternmed.2016.5974","article-title":"Alternative strategies to inpatient hospitalization for acute medical conditions: a systematic review","volume":"176","author":"J Conley","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1160\/TH15-08-0670","article-title":"European Union-28: An annualised cost-of-illness model for venous thromboembolism","volume":"115","author":"S Barco","year":"2016","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.chest.2018.01.035","article-title":"Management of low-risk pulmonary embolism patients without hospitalization: the low-risk pulmonary embolism prospective management study","volume":"154","author":"J R Bledsoe","year":"2018","journal-title":"Chest"},{"issue":"9785","key":"ref27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(11)60824-6","article-title":"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial","volume":"378","author":"D Aujesky","year":"2011","journal-title":"Lancet"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/acem.14108","article-title":"Outpatient treatment of low-risk pulmonary embolism in the era of direct oral anticoagulants: a systematic review","volume":"28","author":"B C Maughan","year":"2021","journal-title":"Acad Emerg Med"},{"issue":"33","key":"ref29","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1093\/eurheartj\/ehab373","article-title":"Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial","volume":"42","author":"P M Roy","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/M18-1206","article-title":"Increasing safe outpatient management of emergency department patients with pulmonary embolism: a controlled pragmatic trial","volume":"169","author":"D R Vinson","year":"2018","journal-title":"Ann Intern Med"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/a-2031-3859","article-title":"Contemporary management and clinical course of acute pulmonary embolism: the COPE study","volume":"123","author":"C Becattini","year":"2023","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.thromres.2013.08.012","article-title":"Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis","volume":"132","author":"S Piran","year":"2013","journal-title":"Thromb Res"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehy873","article-title":"Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis","volume":"40","author":"S Barco","year":"2019","journal-title":"Eur Heart J"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/eurheartj\/ehz367","article-title":"Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial","volume":"41","author":"S Barco","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"ref35","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1161\/CIR.0000000000000707","article-title":"Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association","volume":"140","author":"J Giri","year":"2019","journal-title":"Circulation"},{"issue":"43","key":"ref36","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"S V Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1183\/13993003.00024-2016","article-title":"Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model","volume":"48","author":"C Becattini","year":"2016","journal-title":"Eur Respir J"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1055\/s-0039-3401003","article-title":"Intermediate-high risk pulmonary embolism","volume":"3","author":"R Mirambeaux","year":"2019","journal-title":"TH Open"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ccc.2020.02.003","article-title":"Overview of management of intermediate- and high-risk pulmonary embolism","volume":"36","author":"V F Tapson","year":"2020","journal-title":"Crit Care Clin"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2017.07.029","article-title":"The role of heparin lead-in in the real-world management of acute venous thromboembolism: the PREFER in VTE registry","volume":"157","author":"R Bauersachs","year":"2017","journal-title":"Thromb Res"},{"issue":"24","key":"ref41","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin\u2014a statement for healthcare professionals from the American Heart Association","volume":"103","author":"J Hirsh","year":"2001","journal-title":"Circulation"},{"issue":"04","key":"ref42","first-page":"CD010957","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism","volume":"4","author":"M Li","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijcard.2014.08.136","article-title":"Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis","volume":"177","author":"M C Vedovati","year":"2014","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1615251","article-title":"Direct oral anticoagulants for pulmonary embolism: importance of anatomical extent","volume":"2","author":"M PA Brekelmans","year":"2018","journal-title":"TH Open"},{"issue":"09","key":"ref45","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2352-3026(21)00203-9","article-title":"Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial","volume":"8","author":"F A Klok","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2018.12.013","article-title":"Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry","volume":"174","author":"R Chopard","year":"2019","journal-title":"Thromb Res"},{"issue":"23","key":"ref47","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"S Chatterjee","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurheartj\/ehu218","article-title":"Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis","volume":"36","author":"C Marti","year":"2015","journal-title":"Eur Heart J"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1055\/a-1653-4699","article-title":"Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the pulmonary embolism International THrOmbolysis (PEITHO)-3 trial","volume":"122","author":"O Sanchez","year":"2022","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcin.2021.04.049","article-title":"Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism: the SUNSET sPE trial","volume":"14","author":"E D Avgerinos","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jcin.2020.09.053","article-title":"Indigo aspiration system for treatment of pulmonary embolism: results of the EXTRACT-PE trial","volume":"14","author":"A K Sista","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"09","key":"ref52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jcin.2018.12.022","article-title":"A prospective, single-arm, multicenter trial of catheter-directed mechanical thrombectomy for intermediate-risk acute pulmonary embolism: the FLARE study","volume":"12","author":"T Tu","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/ccd.30091","article-title":"Percutaneous mechanical thrombectomy in a real-world pulmonary embolism population: Interim results of the FLASH registry","volume":"99","author":"C Toma","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"issue":"14","key":"ref54","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcin.2018.04.008","article-title":"A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial","volume":"11","author":"V F Tapson","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jamacardio.2022.3591","article-title":"Catheter-directed thrombolysis vs anticoagulation in patients with acute intermediate-high-risk pulmonary embolism: the CANARY randomized clinical trial","volume":"7","author":"P Sadeghipour","year":"2022","journal-title":"JAMA Cardiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2022.05.011","article-title":"Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study","volume":"251","author":"F A Klok","year":"2022","journal-title":"Am Heart J"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/clc.22216","article-title":"Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge","volume":"37","author":"M Sharifi","year":"2014","journal-title":"Clin Cardiol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/10760296231156414","article-title":"Retrospective analysis of direct-acting oral anticoagulants (DOACs) initiation timing and outcomes after thrombolysis in high- and intermediate-risk pulmonary embolism","volume":"29","author":"A Wolfe","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1177\/1076029618755311","article-title":"Apixaban or rivaroxaban versus warfarin for treatment of submassive pulmonary embolism after catheter-directed thrombolysis","volume":"24","author":"L M Groetzinger","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"16","key":"ref60","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.3390\/jcm11164807","article-title":"An update on the management of acute high-risk pulmonary embolism","volume":"11","author":"R Chopard","year":"2022","journal-title":"J Clin Med"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/jth.14837","article-title":"Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism","volume":"18","author":"J Catella","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1055\/s-0042-1757744","article-title":"On-treatment comparative effectiveness of vitamin K antagonists and direct oral anticoagulants in GARFIELD-VTE, and focus on cancer and renal disease","volume":"6","author":"S Haas","year":"2022","journal-title":"TH Open"},{"issue":"04","key":"ref63","first-page":"747","article-title":"Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial","volume":"116","author":"P Verhamme","year":"2016","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1060028020967635","article-title":"Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes","volume":"55","author":"C YS Cheung","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11239-022-02758-7","article-title":"Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance\u2009<\u200930\u2009mL\/min","volume":"55","author":"L Cline","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref66","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease","volume":"122","author":"A T Cohen","year":"2022","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.14021021","article-title":"Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis","volume":"17","author":"J B Wetmore","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"e005307","DOI":"10.1161\/JAHA.116.005307","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"L Kuo","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.18632\/oncotarget.22755","article-title":"Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis","volume":"9","author":"J Hu","year":"2017","journal-title":"Oncotarget"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"F Nery","year":"2015","journal-title":"Hepatology"},{"issue":"19","key":"ref71","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral anticoagulation in patients with liver disease","volume":"71","author":"A Qamar","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref72","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"07","key":"ref73","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/10600280211047433","article-title":"Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis","volume":"56","author":"M Oldham","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"M Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"05","key":"ref76","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1741-7015-10-4","article-title":"Frailty in primary care: a review of its conceptualization and implications for practice","volume":"10","author":"A Lacas","year":"2012","journal-title":"BMC Med"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"M H Prins","year":"2013","journal-title":"Thromb J"},{"issue":"08","key":"ref79","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.amjmed.2018.02.015","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism","volume":"131","author":"C I Coleman","year":"2018","journal-title":"Am J Med"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/rth2.12036","article-title":"Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism","volume":"1","author":"F Moustafa","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2022.08.001","article-title":"Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment","volume":"218","author":"M Messi","year":"2022","journal-title":"Thromb Res"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-12-21","article-title":"Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants","volume":"12","author":"V Geldhof","year":"2014","journal-title":"Thromb J"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2020.11.022","article-title":"Influence of low body weight on long-term clinical outcomes in patients with venous thromboembolism: from the COMMAND VTE registry","volume":"198","author":"K Kaneda","year":"2021","journal-title":"Thromb Res"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"A T Cohen","year":"2021","journal-title":"Adv Ther"},{"issue":"36","key":"ref86","doi-asserted-by":"crossref","first-page":"e35015","DOI":"10.1097\/MD.0000000000035015","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous thromboembolism: a meta-analysis","volume":"102","author":"H Zhang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"08","key":"ref87","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"K A Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref88","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"B T Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2105-8736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:40:13Z","timestamp":1730806813000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2105-8736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":87,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2105-8736","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]}}}